Email: intake@infuseone.com | Phone: 1-800-581-0645 |
Please refer to website www.infuseone.com for location specific fax numbers

INFUSE ONE

Skyrizi (risankizumab-rzaa) Infusion/Injection Orders

Patient Name: DOB: ☐ Male ☐ Female

Diagnosis (please provide ICD10 code)

☐ New Start Therapy ☐ Continuation of Therapy Date of last dose (if applicable):

☐ NKDA Allergies:

Ordering Provider:

Provider NPI: Phone: Fax:

Practice Address: City: State: Zip Code:

PRE-MEDICATION

☐ Acetaminophen1000mg PO
☐ Diphenhydramine25mg
☐ PO Ceterizine 10mg PO

☐ Solu-Medrol 125mg IVP
☐ Solu-Cortef 100mg IVP
☐ Diphenhydramine 25mg IVP

REQUIRED TESTING/LABS

☑ Clinical/Progress Notes, Labs, Tests supporting primary diagnosis attached

☑ TB status and date (please attach results):

_____

☑ CMP (LFTs and Bilirubin should be monitored at baseline, during induction, and periodically)

SKYRIZI ORDERS

☑ **Initial Skyrizi Induction Infusion:**

Dilute in 250ml D5W and administer intravenously over 1 hour

☐ 600mg IV Infusion @ week 0, 4, and 8

☐ Other: _____

**Maintenance dose: 360mg subcutaneously at week 12, then every 8 weeks thereafter to be administered in home setting via OBI*

Infuse One Standing Orders:

☑ Provide treatment under Infuse One's Clinical Guidelines, Medication Safety Protocol, Emergency Guidelines, and Action Plan for Infusion Reactions.

_____

Provider Name

_____ _____

Provider Signature Date

Serious hypersensitivity reactions, including anaphylaxis, may occur. Skyrizki may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If such an infection develops, do not administer Skyrizi until the infection resolves. Evaluate for TB prior to initiating treatment with Skyrizi. Hepatotoxicity in Treatment of Crohn's Disease: Drug-induced liver injury during induction has been reported. Monitor liver enzymes and bilirubin levels at baseline and, during induction, up to at least 12 weeks of treatment. Monitor thereafter according to routine patient management. Administration of Vaccines: Avoid use of live vaccines.